Press Releases

CRANBURY, N.J., Nov. 10, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2012 financial results on Tuesday, November 15, 2011 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November […]

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.   Recent Highlights Palatin initiated enrollment in its Phase 2B trial

CRANBURY, N.J., Sept. 19, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2011 financial results on Thursday, September 22, 2011 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September

CRANBURY, N.J., Sept. 9, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011, at 12:05 p.m. Eastern Time.  The conference will be held at The Waldorf Astoria in New York, NY. Carl Spana, Ph.D., President

CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate selected by AstraZeneca from its collaborative research

CRANBURY, N.J., June 23, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that Alan W. Dunton, M.D., formally joined Palatin’s Board of Directors on June 22, 2011 as an independent director and member of Palatin’s Audit and Compensation Committees. “Dr. Dunton brings Palatin both substantial drug development experience and clinical research experience,”

CRANBURY, N.J., June 21, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled “Amino Acid Surrogates for Peptidic Constructs.”  The claims in the issued patent cover a series of small molecule mimics for naturally occurring amino acids which can be

CRANBURY, N.J., June 15, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal.  The underlying study was supported by grants from Palatin. Michael A. Perelman, Ph.D., of the New

CRANBURY, N.J., May 16, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its third quarter ended March 31, 2011. Recent Highlights Following a meeting with the U.S. Food and Drug Administration (FDA), Palatin

CRANBURY, N.J., May 12, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended March 31, 2011 financial results and its programs, focusing on the upcoming start of its Phase 2 clinical trial with bremelanotide